ReP USP - Resultado da busca

Filtros : "Perchenet, Loïc" Removido: "MEDICAMENTO (EFEITOS ADVERSOS)" Limpar

Filtros

Collaboration
Normalized affiliation
Non normalized affiliation
- actelion pharmaceuticals ltd, allschwil, switzerland (1)
- assistance publique-hôpitaux de paris, service de pneumologie, hôpital bicêtre, université paris-sud, laboratoire d'excellence en recherche sur le médicament et innovation thérapeutique, and inserm u-999, le kremlin-bicêtre, france (1)
- cardiopulmonary department, ignacio chávez, national heart institute, mexico city, mexico (1)
- clinical department of cardiology and angiology, 1st faculty of medicine, 2nd medical department, charles university, prague, czech republic (1)
- department of cardiology, care hospitals, hyderabad, india (1)

Countries of institutions of collaboration
- bélgica (1)
- canadá (1)
- estados unidos (1)
- frança (1)
- grã-bretanha (reino unido, uk) (1)

Artigo de periodico
Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial (2017)
Mehta, Sanjay; Sastry, Bhagavatula Kutumba Srinivasa; Souza, Rogério; Torbicki, Adam; Ghofrani, Hossein-Ardeschir; Channick, Richard N.; Delcroix, Marion; Pulido, Tomás; Simonneau, Gérald; Wlodarczyk, John; Rubin, Lewis J.; Jansa, Pavel; Hunsche, Elke; Galiè, Nazzareno; Perchenet, Loïc; Sitbon, Olivier
Source: CHEST. Unidade: FM
Subjects: HIPERTENSÃO PULMONAR, QUALIDADE DE VIDA, FARMACOTERAPIA, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MEHTA, Sanjay et al. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. CHEST, v. 151, n. 1, p. 106-118, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.chest.2016.08.1473. Acesso em: 25 out. 2025.
APA
Mehta, S., Sastry, B. K. S., Souza, R., Torbicki, A., Ghofrani, H. -A., Channick, R. N., et al. (2017). Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. CHEST, 151( 1), 106-118. doi:10.1016/j.chest.2016.08.1473
NLM
Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani H-A, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial [Internet]. CHEST. 2017 ; 151( 1): 106-118.[citado 2025 out. 25 ] Available from: https://doi.org/10.1016/j.chest.2016.08.1473
Vancouver
Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani H-A, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial [Internet]. CHEST. 2017 ; 151( 1): 106-118.[citado 2025 out. 25 ] Available from: https://doi.org/10.1016/j.chest.2016.08.1473
Artigo de periodico
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension (2017)
Galiè, Nazzareno; Jansa, Pavel; Pulido, Tomás; Channick Richard N.; Delcroix, Marion; Ghofrani, Hossein-Ardeschir; Le Brun, Franck-Olivier; Mehta, Sanjay; Perchenet, Loïc; Rubin Lewis J.; Sastry, B.K.S.; Simonneau, Gérald; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam
Source: European Heart Journal. Unidade: FM
Subjects: MORTALIDADE, CATETERISMO CARDÍACO, ESTUDOS RANDOMIZADOS, HIPERTENSÃO PULMONAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GALIÈ, Nazzareno et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, v. 38, n. 15, p. 1147-1155, 2017Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehx025. Acesso em: 25 out. 2025.
APA
Galiè, N., Jansa, P., Pulido, T., Channick Richard N.,, Delcroix, M., Ghofrani, H. -A., et al. (2017). SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 38( 15), 1147-1155. doi:10.1093/eurheartj/ehx025
NLM
Galiè N, Jansa P, Pulido T, Channick Richard N., Delcroix M, Ghofrani H-A, Le Brun F-O, Mehta S, Perchenet L, Rubin Lewis J., Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension [Internet]. European Heart Journal. 2017 ; 38( 15): 1147-1155.[citado 2025 out. 25 ] Available from: https://doi.org/10.1093/eurheartj/ehx025
Vancouver
Galiè N, Jansa P, Pulido T, Channick Richard N., Delcroix M, Ghofrani H-A, Le Brun F-O, Mehta S, Perchenet L, Rubin Lewis J., Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension [Internet]. European Heart Journal. 2017 ; 38( 15): 1147-1155.[citado 2025 out. 25 ] Available from: https://doi.org/10.1093/eurheartj/ehx025

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2025